FGFR2 amplification in colorectal adenocarcinoma

FGFR2 is recurrently amplified in 5% of gastric cancers and 1%–4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro ac...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cold Spring Harb Mol Case Stud
Glavni autori: Carter, Jamal H., Cottrell, Catherine E., McNulty, Samantha N., Vigh-Conrad, Katinka A., Lamp, Stephen, Heusel, Jonathan W., Duncavage, Eric J.
Format: Artigo
Jezik:Inglês
Izdano: Cold Spring Harbor Laboratory Press 2017
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5701301/
https://ncbi.nlm.nih.gov/pubmed/28835367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/mcs.a001495
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items